AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04769414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine fluorouracil
Description: chemotherapy protocol given as:~* Gemcitabine 1000mg/m2 IV short infusion~* Leucovorin 400 mg/m2 IV short infusion~* Flourouracil 400 mg/m2 direct IV shot~* Flourouracil 2000 mg/m2 contineous infusion over 46 hours~The whole regimen will be repeated bi-weekly
Study NCT06452667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platelet-rich fibin
Description: Each case will receive 3 sessions of microneedling therapies with one month interval. Each case will receive platelet-rich fibin therapy on one side of the face. The other side of the face was treated with platelet-rich palsma.
Study NCT06452667 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: platelet-rich palsma
Description: Each case will receive 3 sessions of microneedling therapies with one month interval. Each case will receive platelet-rich palsma therapy on one side of the face. The other side of the face was treated with platelet-rich fibin.
Study NCT06261346 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endothelial keratoplasty
Description: Surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea) with brief incubation of the donor tissue in PRGF prior to graft implantation. This incubation will be a one time procedure done to the tissue in the operating room.~The endothelial keratoplasty is 30-45 minutes.
Study NCT06261346 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endothelial keratoplasty
Description: Surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea) with brief incubation of the donor tissue in PRGF prior to graft implantation. This incubation will be a one time procedure done to the tissue in the operating room.~The endothelial keratoplasty is 30-45 minutes.
Study NCT06261346 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGF
Description: Plasma Rich in Growth Factors (PRGF) is a mixture of proteins and growth factors obtained from the blood of the patient.~PRGF incubation lasts 15 minutes. It is a one-time procedure performed on the tissue that will be done in the operating room prior to endothelial keratoplasty.
Study NCT06267729 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD0754
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD0754.~During AZD0754 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD0754 product, subjects will receive treatment with AZD0754 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD0754 administered by intravenous (IV) infusion.
Study NCT05765344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bulevirtide
Description: Administered via subcutaneous injections.
Study NCT04880629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction condition
Description: In the sleep restriction condition, participants are prescribed sleep timings to restrict their sleep by 1 to 2 hours on the night before completing an oral glucose tolerance test (OGTT). Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
Study NCT06407349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Board
Description: communication board based on a functional communication picture of basic needs of categories ( food, clothes, object, and actions)
Study NCT06407349 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Therapy
Description: Traditional Therapy
Study NCT06794931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: The patient will be instructed to follow the modified Mediterranean diet or his usual diet based on the assigned treatment group.
Study NCT06794931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples collection
Description: Additional biological samples will also be collected.
Study NCT06794931 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biological samples collection
Description: Additional biological samples will also be collected.
Study NCT06428409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: Given by IV infusion every 2 weeks (Day 1 and Day 15 of every 4-week cycle)
Study NCT06428409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: 5-FU is administered by IV infusion over 46 to 48 hours every 2 weeks
Study NCT06428409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (LV) or levoleucovorin
Description: LV or levoleucovorin is administered by IV infusion every 2 weeks
Study NCT06428409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Participants are allowed to take rescue medication to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.
Study NCT06428409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supportive care measures
Description: Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents and antiemetic agents. Artificial tear drops or gel may be given as a supportive care for Ocular Surface Toxicity.
Study NCT06326450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality Headset
Description: Augmented simulation of medical crisis scenarios
Study NCT06150560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 50mg administered orally once daily for 52 weeks.
Study NCT06150560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 5mg Amlodipine administered orally once daily for 52 weeks.
Study NCT06150560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules that contain no active drug ingredients administered orally once daily for 52 weeks.
Study NCT06468501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price reduction on healthier foods
Description: Price reduction (10%) on healthier foods based on the UK NPM
Study NCT06468501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price increase to less healthy foods
Description: Price increase (10%) on less healthy foods based on the UK NPM
Study NCT06468501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination of price reduction on healthier foods and price increase on less healthy foods
Description: Combination of price reduction (10%) on healthier foods based on the UK NPM and price increase (10%) on less healthy foods based on the UK NPM
Study NCT06468501 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Existing price structure
Study NCT05085977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TARA-002
Description: Phase 1a, Dose Escalation: First, up to 3 dose levels of TARA-002 (10 KE → 20 KE → 40 KE) will be tested sequentially with 6 weekly intravesical doses starting with the lowest dose using a 3+3 design in a dose escalation manner until the RP2D has been established. If the MTD is not reached, additional cohorts of dose levels higher than 40 KE may be explored.
Study NCT06481306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986470
Description: Specified dose on specified days
Study NCT06481306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study NCT06060626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedation using only Propofol.
Description: Patients in whom only propofol will be administered during sedation.
Study NCT06060626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedation using combination of Propofol and Fentanyl.
Description: Patients in whom combination of propofol and fentanyl will be administered during sedation.
Study NCT03902951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO
Study NCT03902951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO
Study NCT03902951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given SC
Study NCT03902951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03902951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03902951 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT06245564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5%
Description: Ketamine cream 0.5% will be applied in a 4x4 area in the forearm of each participant.
Study NCT06245564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Amitriptyline cream 1% will be applied in a 4x4 area in the forearm of each participant.
Study NCT06245564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine + amitriptyline
Description: A cream containing ketamine 0.5%, amitriptyline 1%, will be applied in a 4x4 area in the forearm of each participant.
Study NCT06245564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: A vehicle cream will be applied in a 4x4 area in the forearm of each participant.
Study NCT06245564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histamine
Description: After the cream removal, itch will be induced using histamine in the first session
Study NCT06245564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: After the cream removal, itch will be induced using cowhage in the second session
Study NCT04682288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin Ocular Implant
Description: Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
Study NCT06462365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRX103
Description: TRX103 infusion via central line.
Study NCT06579989 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound for cough
Description: Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have neurogenic cough for which superior laryngeal nerve block is recommended will undergo this procedure under ultrasound guidance. Patients without neurogenic cough will also be recruited for ultrasound assessment to establish landmarks and normal variation. Patients will be assessed for their comfort with undergoing the procedure and clinicians will be surveyed on the ease and benefit of performing the procedure under ultrasound guidance.
Study NCT06579989 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound for vocal fold atrophy or vocal fold paresis/paralysis
Description: Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have vocal fold atrophy or vocal fold paresis/paralysis for whom injection laryngoplasty is recommended will undergo laryngeal ultrasound prior to the procedure to assess baseline anatomy as well as following the procedure (both immediately following the procedure as well as at follow-up visits) in order to assess the amount of injectate.
Study NCT06579989 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound for dysphagia
Description: Patients with and without swallowing complaints will be enrolled to assess their tongue, suprahyoid and infrahyoid musculature, including muscle identification, bulk and function.
Study NCT06579989 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound for dysphonia
Description: Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have muscle tension dysphonia will undergo ultrasonography during their visit with laryngology or speech language pathology.
Study NCT06106009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07976016
Description: Oral solution, oral suspension or solid oral formulation(s)
Study NCT06167733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VERTICA Active device
Description: VERTICA device with a therapeutic RF energy level
Study NCT06167733 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VERTICA Sham device
Description: VERTICA device with a low, non-therapeutic RF energy level
Study NCT05440422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anifrolumab
Description: This is a double blind placebo-controlled study to characterize whether blocking type I IFN receptor signaling with anifrolumab will lead to improvements in vascular function, decreases in vascular inflammation and modulation of biomarkers of vascular risk in patients with SLE.
Study NCT05440422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-active substance comprised of 25 mM histidine/histidine-HCl, 50 mM lysine-HCl, 130 mM trehalose, and 0.05% (w/v) polysorbate 80, with a pH of 5.9.
Study NCT06550596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Study NCT06550596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Axolotl DualGraft + SOC
Description: Participants will receive weekly applications of Axolotl DualGraft and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Study NCT05411237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: PLD 20 mg/m2 on Day 1 of every 21-day cycle
Study NCT05411237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: PTX 100 mg/m2 on Day 1 of every 21-day cycle
Study NCT05519228 — intervention group
Intervention type: DEVICE
Intervention: ToggleLoc 2.9 mm Soft Tissue System
Description: The ToggleLoc 2.9 mm Soft Tissue System consist of non-resorbable device intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation
Study NCT06785636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pocenbrodib
Description: Pocenbrodib is a selective oral inhibitor of CBP/p300 bromodomain interaction with acetylated lysines on histones.
Study NCT04813445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xingnaojing injection
Description: Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
Study NCT06785636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617
Description: Pocenbrodib alone or in combination
Study NCT06786975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: Tooth will be isolated with cotton rolls, the oral cavity will be dried with small cotton balls and the gingiva around the tooth, and surrounding structures, will be protected with vaseline. Then the silver diamine fluoride solution will be applied to cavitated caries lesions with a micro applicator for one minute approximately. If necessary the solution excess should be removed with a gauze.~Finally the child's teacher will be given the indications for the child to not eat, drink or rinse up to 30 minutes after the treatment, and to evaluate if any sign or symptom related to the tooth appears.
Study NCT06786975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic Restorative Treatment
Description: Participants will be treated with Atraumatic Restorative Treatment (ART) technique. Glass ionomer will be used for cavity filling (Ketac MolarTM, 3M ESPETM) according to manufacter specifications and will be applied with a spatula, followed by finger pressure using vaseline for a few seconds; for occluso-proximal cavities, a matrix band will be used. The restoration will be protected with vaseline and then the occlusion will be checked with articular paper after the initial adjustment (approximately 5 minutes). Finally the child's teacher will be given the indications for the child to not eat, drink or rinse up to 30 minutes after the treatment, and to evaluate if any sign or symptom related to the tooth appears.
Study NCT04802681 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FFR-measurement with different pressure guidewires
Description: Measuring FFR with different pressure guidewires
Study NCT06520384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: Patients will receive radiofrequency.
Study NCT06106009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, oral suspension or solid oral formulation(s)
Study NCT06106009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam oral solution
Study NCT06185907 — intervention group
Intervention type: OTHER
Intervention: Surgery
Description: We referr to resection as that performed in our hospital, and history of major abdominal surgery as interventional surgical procedures in the abdomen with therapeutic intent (e.g., resection) prior to the first hospitalization in our hospital.
Study NCT06084182 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive function, cognitive reserve, functional capacity, reaction time, strength, fatigue, depression and general health assessment
Description: 6-minute walk test and 5-time sit-to-stand test (STS-5) were used for functional capacity assessment. For cognitive reserve assessment, the Cognitive Reserve Index questionnaire was used. Reaction time, cognitive function and visiospatial perception were evaluated with the mobile application. In addition, the Fatigue Severity Scale; Beck Depression Questionnaire and Nottingham Health Profile were used.
Study NCT04806776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24hrs dressings change
Description: The first dressing change and sampling were completed 24 hours after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..Then the second dressing change and sampling were completed 7days later(if there is no clinical indication occur,such leaking,blood).
Study NCT04806776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7days dressings change
Description: The first dressing change and sampling were completed 7 days after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..(if there is no clinical indication occur,such leaking,blood).
Study NCT05325554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal rehabilitation
Description: Multimodal rehabilitation
Study NCT05657314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active Comparator
Description: Consists of 15 grams of pea protein
Study NCT05657314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Consists of 15 grams of pea protein
Study NCT06520384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol 30%
Description: Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 30% alcohol in 0.25% bupivacaine.
Study NCT06520384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol 50%
Description: Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 50% alcohol in 0.25% bupivacaine.
Study NCT06520384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol 70%
Description: Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 70% alcohol in 0.25% bupivacaine.
Study NCT06185296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent telemonitoring
Description: Telemonitoring using CGM, insulin pen data, and Fitbit data supported by data-driven decision support.
Study NCT06185296 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitoring
Description: Telemonitoring using CGM, insulin pen data, and Fitbit data
Study NCT05097001 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DBS programming
Description: DBS readjustment based on COMPUTER or CLINICAL program